| |
Fig. 2. Myo10-MO disrupted expression of neural crest genes. (A) Embryos were injected with control or Myo10-MO (10 ng) in one cell at the two-cell stage, thus labeling one side (labeled with red-gal staining, bottom half in dorsal view and right panel in lateral view, marked by ). The subsequent expression of neural or neural crest genes was examined at later stages. While the expression of neural marker Sox3 was unaffected, the levels of neural crest genes Snail2, Sox10 and Twist were altered in the half of the embryo that received Myo10-MO. Co-expression of a low dose (50–100 pg) Myo10 RNA efficiently rescued the defect. (B) Percentages of embryos with different levels of neural crest gene expression (combining Snail2, Sox10 and Twist) at neurula stages. While over 75% of control-MO injected embryos showed symmetric neural crest gene expression, Myo10-MOs reduced the neural crest gene expression severely in over 25% of embryos and altered the expression mildly in 45% of the embryos. Nearly 70% of the embryos were rescued to normal levels by coexpressing Myo10 RNA. (C) Percentage of embryos with defective neural crest migration indicated by the expression of Sox10 and Twist at tailbud stages. Myo10-MOs lead to shorter and disorganized CNC migration in about 70% of the embryos and co-injection of Myo10 RNA reduced that to 18%. |
